Source Bio provides an integrated, cloud‑connected platform that automates the design, manufacturing, and delivery of gene‑editing therapeutics.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gene‑therapy development relies on lengthy, low‑throughput manufacturing pipelines and limited delivery platforms, which increase costs and restrict patient access to treatments.
Solution
Source Bio offers an integrated platform that streamlines the design, production, and delivery of gene‑editing therapeutics. By combining automated vector engineering, scalable biomanufacturing, and novel delivery modalities, the platform reduces development timelines and manufacturing expenses. Integrated analytics and quality‑control tools ensure consistent product potency and safety across batches. The system is delivered as a cloud‑connected service that enables biotech companies to launch clinical programs faster while maintaining regulatory compliance.
Target Audience
Primary customers are biotech and pharmaceutical companies developing gene‑therapy candidates, as well as contract manufacturing organizations seeking a flexible, end‑to‑end solution.
Features
- Automated design suite for viral and non‑viral vectors with AI‑guided optimization
- Scalable, GMP‑compatible bioprocessing modules that reduce batch‑to‑batch variability
- Modular delivery technologies (e.g., lipid nanoparticles, engineered capsids) tailored to target tissues
- Real‑time analytics dashboard for process monitoring, potency assessment, and regulatory reporting
- Cloud‑based API for seamless integration with existing R&D workflows and data management systems